Podoplanin and CD34 in peripheral nerve sheath tumours: focus on neurofibromatosis 1-associated atypical neurofibroma.

TY - JOUR

T1 - Podoplanin and CD34 in peripheral nerve sheath tumours: focus on neurofibromatosis 1-associated atypical neurofibroma.

AU - Naber, Urs

AU - Friedrich, Reinhard

AU - Glatzel, Markus

AU - Mautner, Viktor Felix

AU - Hagel, Christian

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Patients suffering from neurofibromatosis type 1 and 2 (NF1 and NF2) are the main risk groups to develop peripheral nerve sheath tumours (PNSTs). In the present study, adhesion molecules CD34 and podoplanin were assessed in regard to their value for tumour classification and as indicators for tumour progression. A total of 103 NF1-, NF2- and schwannomatosis-associated neurofibromas, schwannomas and malignant peripheral nerve sheath tumours (MPNST), as well as 20 sporadic vestibular schwannomas and 9 control tissue samples, were labelled immunohistochemically for detection of podoplanin and CD34. CD34 was shown to be expressed in MPNST and all benign PNSTs except for the compact cellular parts of both, schwannomas and atypical neurofibromas. Podoplanin showed an inverse expression pattern to CD34 labelling mainly the compact parts of schwannoma and atypical neurofibroma. MPNSTs were characterized by strong podoplanin staining at the invasive front. NF1-patients who suffered from atypical neurofibromas did not develop MPNST at a higher frequency than other NF1-patients, although these tumours expressed podoplanin. Ki-67 proliferation indices did not differ significantly between neurofibromas, atypical neurofibromas and schwannomas. In accordance with other studies, CD34 was found to be of limited value for classification and grading of PNST due to its ubiquitous expression. Podoplanin expression in schwannoma and atypical neurofibroma adds to other phenotypic and genotypic similarities between these tumours, like nuclear atypia, regressive changes and euploid polyploidisation. Podoplanin expression in atypical neurofibroma was not associated with tumour progression towards MPNST.

AB - Patients suffering from neurofibromatosis type 1 and 2 (NF1 and NF2) are the main risk groups to develop peripheral nerve sheath tumours (PNSTs). In the present study, adhesion molecules CD34 and podoplanin were assessed in regard to their value for tumour classification and as indicators for tumour progression. A total of 103 NF1-, NF2- and schwannomatosis-associated neurofibromas, schwannomas and malignant peripheral nerve sheath tumours (MPNST), as well as 20 sporadic vestibular schwannomas and 9 control tissue samples, were labelled immunohistochemically for detection of podoplanin and CD34. CD34 was shown to be expressed in MPNST and all benign PNSTs except for the compact cellular parts of both, schwannomas and atypical neurofibromas. Podoplanin showed an inverse expression pattern to CD34 labelling mainly the compact parts of schwannoma and atypical neurofibroma. MPNSTs were characterized by strong podoplanin staining at the invasive front. NF1-patients who suffered from atypical neurofibromas did not develop MPNST at a higher frequency than other NF1-patients, although these tumours expressed podoplanin. Ki-67 proliferation indices did not differ significantly between neurofibromas, atypical neurofibromas and schwannomas. In accordance with other studies, CD34 was found to be of limited value for classification and grading of PNST due to its ubiquitous expression. Podoplanin expression in schwannoma and atypical neurofibroma adds to other phenotypic and genotypic similarities between these tumours, like nuclear atypia, regressive changes and euploid polyploidisation. Podoplanin expression in atypical neurofibroma was not associated with tumour progression towards MPNST.

KW - Adult

KW - Antigens, CD34

KW - Disease Progression

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - Male

KW - Membrane Glycoproteins

KW - Nerve Sheath Neoplasms

KW - Neurilemmoma

KW - Neurofibromatosis 1

KW - Tumor Markers, Biological

U2 - 10.1007/s11060-010-0385-4

DO - 10.1007/s11060-010-0385-4

M3 - SCORING: Journal article

C2 - 20821344

VL - 103

SP - 239

EP - 245

JO - J NEURO-ONCOL

JF - J NEURO-ONCOL

SN - 0167-594X

IS - 2

M1 - 2

ER -